Dicerna Pharmaceuticals, Inc. Financials

Market Capitalization $2.93 Billion as of Dec. 1, 2021

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-25.14
Forward PE	-19.11
Price to Sales TTM	$15.44
Price to Book MRQ	$27.64
Enterprise to Revenue	12.84
Enterprise to EBITDA	-21.21

Financial Reports as of Sep. 30, 2021

Financials

Fiscal Year Ends	2020-12-31
Most Recent Quarter	2021-09-30
Profit Margin	-64.53%
Operating Margin	-62.88%
Return on Assets TTM	-10.43%
Return on Equity TTM	-95.22%

Income Statement

Revenue TTM	$192,850,000
Revenue per Share TTM	$2.52
Quarterly Revenue Growth	28.80%
Gross Profit TTM	$-41,077,000
EBITDA	$-116,730,000
Net Income to Common TTM	$-124,438,000
Diluted EPS TTM	$-1.63
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$565,508,992
Total Cash per Share MRQ	$7.26
Total Debt MRQ	$
Total Debt to Equity MRQ	59.84
Current Ratio MRQ	2.46
Book Value per Share MRQ	$1.38

Cash Flow

Operating Cash Flow TTM	$21,050,000
Levered Free Cash Flow TTM	$-45,580,624

DRNA Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	77,909,504
Float Shares	60,148,949
Avg 10 Volume	2,478,191
Avg 30 Volume	None
Shares Short	4,771,494
Short Ratio	0.84
Short % of Shares	6.39%
% Held by Insiders	7.43%
% Held by Institutions	88.54%

Stock Price Summary

Beta	0.79
Fifty Two Week Low	$19.06
Fifty Two Week High	$40.14
Fifty Two Week Change	0.59%
Day 50 MA	$31.45
Day 200 MA	$28.97

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$
Trailing Annual Dividend Yield	%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date